Rejected at 3:40 a.m. Nov, 01, 2023 ] by Cameron
Author: madari.armin
Related Note: 1472502628127 1
Rationale for change

The drug class should be recalled as a whole, or else its just a A/B choices (asking Non-DHP or DHP). Therefor, CCB should be included in Cloze-2.

Rejection reason

AMBOSS lists several other Tx options for Raynaud, change would make cloze ambiguous

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::02_Pathology::34_Raynaud_phenomenon #AK_Step3_v12::#UWorld::5926 #AK_Step2_v12::#SketchyIM::07_Rheumatology::07_Systemic_Diseases::03_Scleroderma #AK_Step1_v12::#AMBOSS::4_03oi #PANCE::EOR::IM #AK_Step1_v12::#Bootcamp::Musculoskeletal::03_Rheumatologic_Disease::10_Raynaud_Phenomenon #AK_Step1_v12::#SketchyPharm::02_Cardio_&_Renal::03_Antihypertensives::01_Calcium_channel_blockers #AK_Step1_v12::#Pathoma::18_MSK::04_Skeletal_Muscle::NMJ #AK_Step2_v12::#Resources_by_rotation::FM::ome::rheum::other_connective_tissue #AK_Step2_v12::#AMBOSS::I30YPf #AK_Step2_v12::#Resources_by_rotation::IM::ome::rheum::other_connective_tissue #AK_Step1_v12::#Bootcamp::Cardiology::07_Vasodilation_and_Vasoconstriction::04_Pharmacologic_Targets #AK_Step2_v12::Original_decks::Dorian::im::ome::rheum::other_connective_tissue #AK_Step2_v12::#UWorld::Step::6946 #AK_Step1_v12::#Pixorize::03_Pharmacology::22_Cardiovascular_(New)::03_DHP_Calcium_Channel_Blockers #AK_Step1_v12::^Systems::Cardio::Pharmacology #AK_Step1_v12::#OME::PreClinical::General_Physiology::Skeletal_Muscle #AK_Step1_v12::#FirstAid::07_Cardiovascular::05_Pharm::03_Calcium_channel_blockers #AK_Step1_v12::^Systems::Musculoskeletal::Pathology #AK_Step2_v12::Original_decks::Dorian::fam::ome::rheum::other_connective_tissue !AK_UpdateTags::SkinOfColor::NeedsImage #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Musculoskeletal::Musculoskeletal_Pathology #AK_Step2_v12::#OME::01_Medicine::08_Rheumatology::04_Other_Connective_Tissue #AK_Step2_v12::!Shelf::FM !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step2_v12::!Shelf::FM::no_dupes #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step2_v12::#Subjects::Immunology_&_Pathology::02_Immunology::Autoimmune_Disorders::Raynaud_Syndrome #AK_Step2_v12::#UWorld::#UWSA1 #AK_Step1_v12::#Physeo::09_Pharm::10_Cardiac::02_Calcium_Channel_Blockers #AK_Step2_v12::!Shelf::IM #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Pathoma::18_MSK::04_Skeletal_Muscle #AK_Step1_v12::#Physeo::^physeo_image_update !AK_UpdateTags::Step1decks::Zanki-Step-Decks::Zanki-Musculoskeletal::Musculoskeletal-Pathology #AK_Step2_v12::#FirstAid::08_MSK::02_Upper_Extremity::09_Raynaud_Phenomenon #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::#UWorld::Step::9906 #AK_Step2_v12::#UWorld::COMLEX::101876 #AK_Step1_v12::#Physeo::09_Pharm::10_Cardiac::01_Hypertension_Treatment #AK_Step2_v12::#SketchyIM::07_Rheumatology::07_Systemic_Diseases::02_Systemic_Lupus_Erythematosus_SOAP